News and Trends 13 Nov 2017 British Biotech Gets PRIME Designation for its Brittle Bones Drug The EMA has awarded PRIME Designation to Mereo BioPharma’s osteogenesis imperfecta drug, a condition for which there is no treatment on the market. Mereo acquires, develops and commercializes therapies for patients with rare diseases. It was set up by Denise Scots-Knight, one of our top women entrepreneurs, in 2015 and already has a market cap […] November 13, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
Sponsored 13 Nov 2017 Top 5 Things to Know About Immunotherapies – A Review Immunotherapy – A big word with much meaning. There’s no use in talking about their history. The fact that immunotherapies seem to be the next big thing in biotech is reason enough to discuss them. For this purpose, we have caught up with Etienne Drouet, Vice President of Strategic Development at SynteractHCR, an international CRO. […] November 13, 2017 - 13 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2017 Roche Partners with French Startup to Diagnose Septic Shock In its first partnership with a biotech startup, Roche Diagnostics will help develop a blood test to accompany Inotrem’s experimental therapy for septic shock. Roche Diagnostics has announced a research collaboration with Inotrem, a biotech startup based in Nancy, France. The deal, for which the amount was undisclosed, concerns the development of a companion diagnostic test […] November 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 9 Nov 2017 Interview with Europe’s Leader in Biotech Partnerships I talked with Werner Lanthaler, CEO of Evotec, during Bio Europe 2017 to ask him what the key is to his company’s great success in supporting biotech innovation and establishing strategic partnerships. Evotec started off as a contract research organization in Hamburg back in 1993. Today it has over 2,000 employees worldwide, its own pipeline […] November 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Nov 2017 Doctors Use Genetically Modified Stem Cells to Give a Boy New Skin The ‘butterfly child’ who lost 80% of his skin has been successfully treated. The boy is now able to go to school and enjoy life with family and friends. A medical team from the Ruhr-Universität Bochum’s burn unit and the Center for Regenerative Medicine at the University of Modena have treated a boy suffering from […] November 9, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2017 Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease. Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now. In exchange for an […] November 9, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 9 Nov 2017 Meet the Spin-Out Queen Taking on Neurological Diseases Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […] November 9, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 8 Nov 2017 Interviewing Europe’s Most Intense Investor about Trends in Biotech I interviewed Kate Bingham of SV Health Investors about Alzheimer’s, checkpoint inhibitors, gender diversity and more at BIO Europe. BIO Europe 2017 was off to a racing start on Monday morning when I chatted with Kate Bingham, Managing Partner of SV Health Investors, formerly SV Life Sciences. Since she joined the firm in 1991, she […] November 8, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […] November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development InflaRx has announced that its shares will cost $15 when they’re launched for the company’s IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal antibodies targeted towards the complement system to treat potentially fatal inflammatory diseases. The company that its share will cost $15 (€13) when the company launches its IPO, […] November 8, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 Phase I Results are in for Swedish Biotech’s Cancer Antibody Alligator Bioscience has reported promising results from a Phase I study, where its candidate has been well tolerated in patients with late-stage solid tumors. Alligator Bioscience, located in Lund, Sweden, develops antibody-based immunotherapies to fight cancer. Its pipeline includes clinical and pre-clinical drug candidates, including ADC-1013 and ATOR-1015, as well as novel research candidates. The company […] November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2017 British Researchers Find Thought Police to Treat Neurological Disorders Cambridge University scientists have identified a chemical in the brain that blocks unwanted thoughts, offering a new avenue to treat neurological disorders. Researchers at the University of Cambridge have found identified a new process in the brain’s prefrontal cortex that can block our thoughts. The research, published in Nature Communications, demonstrated that the ability to block unwanted thoughts […] November 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email